What You Should Know:

您应该知道：

–       Atropos Health, the pioneer in translating real-world clinical data into high-quality personalized real-world evidence for care, today announced a $30 million Series B on the heels of the adoption of its Generative AI platform (GENEVA OSTM) by healthcare institutions, data platforms, research institutions, Life Sciences companies and more..

–Atropos Health是将现实世界的临床数据转化为高质量个性化现实世界护理证据的先驱，继医疗机构、数据平台、研究机构、生命科学公司等采用其生成性人工智能平台（GENEVA OSTM）之后，今天宣布推出3000万美元的B系列产品。。

–       The funding was led by Valtruis, with participation from new strategic investors including Cencora Ventures, McKesson Ventures, and Merck GHI Fund, along with existing investors Breyer Capital, Emerson Collective, and Presidio Ventures.

–资金由Valtruis牵头，新战略投资者（包括Cencora Ventures、McKesson Ventures和Merck GHI Fund）以及现有投资者Breyer Capital、Emerson Collective和Presido Ventures共同参与。

Atropos Health: Pioneering Real-World Evidence and AI Innovations in Healthcare

Atropos Health：开创性的现实世界证据和医疗保健领域的人工智能创新

Founded in 2019 as a spin-out of Stanford University’s “Green Button” technology, Atropos Health was established by Brigham Hyde Ph.D., Nigam Shah MBBS, Ph.D., and Saurabh Gombar M.D., Ph.D., who are leaders in AI applications and Real-world Evidence Research in Healthcare. Their mission is to democratize access to high-quality real-world evidence to enhance decision-making and healthcare outcomes.

Atropos Health成立于2019年，是斯坦福大学“绿色按钮”技术的衍生产品，由Brigham Hyde博士、Nigam Shah MBBS博士和Saurabh Gombar博士创立，他们是人工智能应用和医疗保健现实世界证据研究的领军人物。他们的使命是使获得高质量真实世界证据的机会民主化，以增强决策和医疗保健成果。

Since its inception, Atropos Health has become a pioneer in generative AI, offering unique user experiences like ChatRWDTM, which dramatically reduces the time required to produce high-quality publication-grade real-world evidence from months to minutes through a chat-based AI co-pilot..

自成立以来，Atropos Health已成为生成性人工智能的先驱，提供独特的用户体验，如ChatRWDTM，这大大减少了通过基于聊天的人工智能联合试点产生高质量出版物级真实世界证据所需的时间，从数月减少到数分钟。。

With new funding, Atropos Health aims to strengthen its position in value-based care. The company’s suite of evidence-generating applications supports whole-person care and value-based performance, already utilized by partners such as Arcadia. Atropos Health enables healthcare organizations to accelerate appropriate clinical decision-making, promoting high-value, low-cost care tailored to patients’ unique physiology.

有了新的资金，Atropos Health旨在加强其在基于价值的护理中的地位。该公司的一套证据生成应用程序支持全人护理和基于价值的绩效，阿卡迪亚等合作伙伴已经在使用这些应用程序。Atropos Health使医疗保健组织能够加速适当的临床决策，促进针对患者独特生理的高价值，低成本护理。

To advance this mission, the company is welcoming value-based care expert Mike Spadafore to its board..

为了推进这一使命，该公司欢迎基于价值的护理专家迈克·斯帕达福（MikeSpadafore）加入董事会。。

As part of this funding round, Atropos Health will form strategic partnerships with life sciences and vertically integrated healthcare entities. Through a collaboration with Cencora, a leading global pharmaceutical solutions organization, Atropos Health will extend its real-world evidence platform to oncology and specialty care.

作为这轮融资的一部分，Atropos Health将与生命科学和垂直整合的医疗保健实体形成战略伙伴关系。通过与全球领先的药物解决方案组织Cencora的合作，Atropos Health将其真实世界的证据平台扩展到肿瘤学和专科护理。

In the fast-evolving field of Oncology, where patient outcomes are critical, oncologists and researchers can now utilize the Atropos Evidence Network, comprising millions of anonymized patient records converted into high-quality evidence, to inform their decisions. Pharmaceutical clients, including Janssen Research & Development, LLC (a Johnson & Johnson company), can leverage this evidence network to drive crucial R&D initiatives and expedite the development of new treatments..

在快速发展的肿瘤学领域，患者的预后至关重要，肿瘤学家和研究人员现在可以利用Atropos证据网络，将数百万匿名患者记录转换为高质量证据，为他们的决策提供信息。包括强生公司Janssen Research&Development，LLC在内的制药客户可以利用这一证据网络来推动关键的研发计划，并加快新疗法的开发。。

Launched in Beta in Q4 of 2023, ChatRWD transforms the production of high-quality real-world evidence, reducing the process from months to minutes through a user-friendly chat interface designed for clinical and research purposes. While the speed of ChatRWD is groundbreaking, Atropos Health prioritizes accuracy and transparency of results.

ChatRWD于2023年第4季度推出测试版，通过为临床和研究目的设计的用户友好聊天界面，将高质量真实世界证据的产生过程从几个月缩短到几分钟。虽然聊天室的速度是开创性的，但Atropos Health优先考虑结果的准确性和透明度。

Built on the GENEVA OS technology, ChatRWD is an LLM-independent framework that ensures LLM security and integrity, eliminating the risk of hallucinations unacceptable in clinical evidence. An upcoming publication will detail this approach and its benefits for generating accurate evidence. Investment from this funding round will support the full launch of ChatRWD, with the potential to democratize access to high-quality, accurate, transparent, and personalized Real-World Evidence..

ChatRWD基于GENEVA操作系统技术，是一个独立于LLM的框架，可确保LLM的安全性和完整性，消除临床证据中不可接受的幻觉风险。即将出版的出版物将详细介绍这种方法及其产生准确证据的好处。这一轮融资的投资将支持ChatRWD的全面推出，有可能使人们获得高质量、准确、透明和个性化的真实世界证据。。

Atropos Health, the developer of GENEVA OSTM, provides an operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations partner with Atropos Health to bridge evidence gaps from bench to bedside, enhancing individual patient outcomes with data-driven care and accelerating research that advances medical science..

日内瓦OSTM的开发人员Atropos Health提供了一个操作系统，可以通过强大的现实数据网络快速提供医疗保健证据。医疗保健和生命科学组织与Atropos Health合作，弥合从实验室到床边的证据差距，通过数据驱动的护理提高个体患者的结果，并加速推进医学科学的研究。。

“As excitement over the application of Generative AI technology in healthcare turns from potential to practical applications, the focus of providers, life sciences, and other healthcare stakeholders turns to quality, transparency, and automation backed by tangible ROI. For decades, high-quality clinical evidence has served as the currency of value in healthcare.

“随着对生成性人工智能技术在医疗保健中的应用的兴奋从潜在应用转向实际应用，提供者，生命科学和其他医疗保健利益相关者的重点转向由有形投资回报率支持的质量，透明度和自动化。几十年来，高质量的临床证据一直是医疗保健的价值货币。

Atropos Health is built on investment in scaling the production of high quality, transparent, and now real-time evidence production that matches the standards of the clinical and research communities,” said Brigham Hyde, CEO and Co-Founder of Atropos Health. “This funding round, which includes multiple major strategic stakeholders in the healthcare ecosystem, is validation that our platform is rapidly becoming the standard not only for automation and user experience, but also as the trusted quality layer between healthcare data, and the critical evidence needed to better inform patient care, research, and policy.”.

Atropos Health的基础是投资于扩大高质量，透明，现在是实时证据生产，符合临床和研究社区的标准，”Atropos Health首席执行官兼联合创始人Brigham Hyde说。“这轮融资包括医疗保健生态系统中的多个主要战略利益相关者，验证了我们的平台正在迅速成为标准，不仅是自动化和用户体验的标准，而且是医疗保健数据与更好地告知患者护理，研究和政策所需的关键证据之间值得信赖的质量层。”。